SCHEMBL104764

SCHEMBL104764

NC(=O)c1ccc(B(O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 4/20 0.50
TSHR P16473 3/20 0.50
PARP4 Q9UKK3 2/20 0.50
PARP1 P09874 2/20 0.50
PARP15 Q460N3 2/20 0.50
ALDH1A1 P00352 1/20 0.50
KMT2A Q03164 1/20 0.50
PARP14 Q460N5 1/20 0.50
PARP16 Q8N5Y8 1/20 0.50
PARP11 Q9NR21 1/20 0.50
POLB P06746 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 1/20 0.50
CYP2C19 P33261 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terephthalamide SCHEMBL29109497 0.89 PARP1 (0.62) PARP10TSHRPARP4PARP1PARP15
SCHEMBL16171746 0.81 PARP10 (0.48) PARP10TSHRPARP4PARP1PARP15
Terephthalamide SCHEMBL23774 0.81 PARP1 (0.71) PARP10TSHRPARP4PARP1PARP15
SCHEMBL24689977 0.79 TRPV1 (0.69) CA2CA1
Hydrochlorthiazide SCHEMBL28867104 0.79 CHEK2 (0.38) PARP10TSHRPARP4PARP1PARP15
Terephthalamide SCHEMBL1906838 0.78 PARP1 (0.67) PARP10TSHRPARP4PARP1PARP15
Terephthalamide SCHEMBL15328883 0.78 PARP1 (0.67) PARP10TSHRPARP4PARP1PARP15
Terephthalamide SCHEMBL11512422 0.78 PARP1 (0.67) PARP10TSHRPARP4PARP1PARP15
Terephthalamide SCHEMBL7508927 0.78 PARP1 (0.67) PARP10TSHRPARP4PARP1PARP15
Terephthalamide SCHEMBL689841 0.78 PARP1 (0.67) PARP10TSHRPARP4PARP1PARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
CN-119735600-A 3-Ureido substituted thieno [2,3-b ] pyridine compound and preparation method and application thereof 华东师范大学 2025-04-01 CN claimed
CN-119286228-A High-resistant Wen Qianshui motor winding wire and preparation method thereof 河北国潜线缆有限责任公司 2025-01-10 CN claimed
CN-115959993-B Synthesis method of 2-aryl propionic acid compound 山东中医药大学 2025-01-07 CN claimed
CN-119177083-A Preparation and application of gamma-ray radiation resistant hetero element modified polyimide resin coating 中国科学院兰州化学物理研究所 2024-12-24 CN claimed
US-12102715-B1 ROS-responsive liposomes for specific targeting VERILY LIFE SCIENCES LLC (US) 2024-10-01 US claimed
WO-2024169524-A1 RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF 成都纽瑞特医疗科技股份有限公司 2024-08-22 WO claimed
WO-2024169525-A1 BORON-CONTAINING DRUG AND PREPARATION METHOD THEREFOR 成都纽瑞特医疗科技股份有限公司 2024-08-22 WO claimed
WO-2024016826-A1 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF 杭州市第七人民医院 2024-01-25 WO claimed
EP-0927217-A4 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RES INST LTD (AU) 2003-04-23 EP claimed
EP-0928306-A4 ANTIVIRAL LINEAR POLYMERS BIOMOLECULAR RES INST LTD (AU) 2003-04-16 EP claimed
EP-1019414-A4 PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID COMMW SCIENT IND RES ORG (AU) 2002-05-29 EP claimed
US-20020025919-A1 Antiviral linear polymers STARPHARMA PTY LIMITED (AU) 2002-02-28 US claimed
EP-1019414-A1 PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-07-19 EP claimed
EP-0928306-A1 ANTIVIRAL LINEAR POLYMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1999-07-14 EP claimed
EP-0927217-A1 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1999-07-07 EP claimed
WO-1999012940-A1 PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1999-03-18 WO claimed
WO-1998003572-A1 ANTIVIRAL LINEAR POLYMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1998-01-29 WO claimed
WO-1998003573-A1 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1998-01-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025919-A1 Antiviral linear polymers SARS1, MAVS, EIF2AK2 PARP10 688/4885TSHR 4315/4885PARP4 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.